🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study to Examine the Effect of the Diuretic Furosemide on the Plasma Levels of Toxins and the Removal of Toxins from the Blood in Patients with Chronic Kidney Disease

Recruitingn/aAges 18 Years - anyAllUMC Utrecht
NCT06750575 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to examine the interaction between the diuretic furosemide and certain toxins called protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). The main question it aims to answer is: what is the effect of furosemide on plasma levels of PBUTs in patients with CKD? Besides, the investigators will also look at the effect of furosemide on the excretion of PBUTs via the urine. Participants will be included in the study once they will be prescribed furosemide as part of routine patient care. Before they start with the furosemide treatment, patients will undergo the following: * Blood pressure measurement * Blood sample withdrawal * Urine sample collection * 12-hour urine collection Then, one to four weeks after starting with furosemide treatment, patients will undergo the following: * Blood pressure measurement * Blood sample

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * An age of 18 years or older * An eGFR \<60 mL/min/1.73m2 for at least three months (diagnosis of CKD stage 3-5) * An indication for the start of treatment with furosemide as part of routine patient care * Willingness to participate in the study and a signed informed consent Exclusion Criteria: * Patients who are already on furosemide treatment * Patients with a liver disease with hyperbilirubinemia * Patients who receive any type of renal replacement therapy (peritoneal dialysis, haemodialysis) * Patients with end-stage renal failure without residual diuresis * Patients who will start with medication simultaneously with start of furosemide treatment that might interfere with PBUT excretion or PBUT protein binding * Patients who are incapacitated
💊

What it tests

  • Invasive measurements
📍

Where

1 site
University Medical Center Utrecht (UMCU)
Utrecht, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy